Navigation Links
Odyssey Thera Announces Collaboration With Mitsubishi Tanabe Pharma Corporation, and Issuance of Core Patent in Japan

SAN RAMON, Calif., May 15 /PRNewswire/ -- Odyssey Thera, Inc. announced today the initiation of a collaboration with leading Japanese pharmaceutical company Mitsubishi Tanabe Pharma Corporation. The alliance involves the analysis of drug candidates from a number of Mitsubishi Tanabe preclinical programs. Odyssey also announced the issuance of Japanese patent number JP 4262778, entitled "Protein fragment complementation assays for the detection of biological or drug interactions."

"We look forward to applying our patented human cell analysis technologies and proprietary drug profiling strategies to enhance Mitsubishi Tanabe's promising drug discovery programs," said Dr. John Westwick, President and CEO of Odyssey Thera. "Our partnership with Mitsubishi Tanabe, and the issuance of our Japanese patent, reflect our objective of making our unique knowledge base and enabling technologies available to quality partners around the globe."

Odyssey Thera will apply its patented Protein-fragment Complementation Assay (PCA), proprietary High Context Screening infrastructure, unique institutional knowledge, and state-of-the-art data analysis strategies in the collaboration to yield valuable insights related to drug selectivity, safety, and mechanisms of action. Financial terms of the collaboration were not disclosed.

About Odyssey Thera

Odyssey Thera, Inc. is a drug discovery company committed to identifying novel drug candidates for oncology and other chronic diseases. Odyssey Thera's live cell, pathway-based approach centers on its proprietary Protein-fragment Complementation Assay (PCA) technology and unique High Context Screening platform. Using these capabilities, Odyssey scientists have gained unique knowledge regarding cellular pathways and drug mechanisms. Odyssey's highly experienced team is using these capabilities to mine cellular systems and discover novel drug candidates for internal programs, and in partnerships with top pharmaceutical companies. To learn more about Odyssey Thera, please visit

SOURCE Odyssey Thera, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Odyssey Thera Granted U.S. Patent for Novel GPCR Assay Strategy
2. Technical Note: E-PAGE(TM) 48- and 96-Well Gels on the Odyssey(R) Infrared Imaging System
3. LI-COR Introduces the Odyssey(R) Two-Color NIR Fluorescent Protein Molecular Weight Marker
4. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
5. Stereotaxis Highlights a Transatlantic Arrhythmia Procedure Collaboration With the Odyssey(TM) Network
6. Odyssey Thera Granted U.S. Patent for Animal Imaging
7. Cell Therapeutics Closes Italian Facility, Reduces Headcount and Expects to Cut $14 Million in Operating Expenses
8. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
9. Orexigen(R) Therapeutics to Present at Upcoming Meetings
10. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
11. Cell Therapeutics to Exchange up to $89.2 million of Its Outstanding Convertible Notes in a Modified Dutch Auction Tender Offer
Post Your Comments:
(Date:11/23/2015)... VA (PRWEB) , ... November 23, 2015 , ... Noblis, ... McCarthy , former Director, Plans and Programs, National Geospatial Intelligence Agency (NGA), has joined ... us with an incredibly distinguished career in the intelligence community and the private sector,” ...
(Date:11/23/2015)... , November 23, 2015 biochar ... million in 2015, and it is expected to grow ... The factors driving the growth of the global market ... sequestration property of biochar, increased government initiatives and stringent ... initiatives and stringent environment regulations are the key drivers ...
(Date:11/23/2015)... Fla. , Nov. 23, 2015  Oxis ... Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: ... of Minnesota Masonic Cancer Center received notification from ... they can proceed with their planned combination Phase ... worldwide exclusive rights to develop and commercialize OXS-1550, ...
(Date:11/23/2015)... 2015 ) ... Global Molecular Diagnostics Market: Latest Instrumentation and ... to their offering.  --> ... "2016 Global Molecular Diagnostics Market: Latest Instrumentation ...  report to their offering.  --> ...
Breaking Biology Technology:
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... ANN ARBOR, Mich. , Oct. 29, 2015 ... with Eurofins Genomics for U.S. distribution of its ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq ... DNA to enable the preparation of NGS libraries ... in plasma for diagnostic and prognostic applications in ...
(Date:10/27/2015)... , Oct. 27, 2015 In the ... issues of concern for various industry verticals such as ... due to the growing demand for secure & simplified ... various ,sectors, such as hacking of bank accounts, misuse ... electronic equipment such as PC,s, laptops, and smartphones are ...
Breaking Biology News(10 mins):